Stay updated on Pembro + Lenalid Post-ASCT in High-Risk MM Clinical Trial
Sign up to get notified when there's something new on the Pembro + Lenalid Post-ASCT in High-Risk MM Clinical Trial page.
Latest updates to the Pembro + Lenalid Post-ASCT in High-Risk MM Clinical Trial page
- Check4 days agoChange DetectedRemoved the disease label 'Multiple myeloma' and related topics such as MedlinePlus Genetics. This reduces disease context and discoverability of the study for users searching by condition or genetics resources.SummaryDifference0.5%
- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedAdded MedlinePlus Genetics topic on multiple myeloma to expand core content.SummaryDifference0.1%
- Check25 days agoChange DetectedAdded two key research citations (with complete details) and removed/adjusted erratum notes for those citations; this improves bibliographic accuracy and credibility without changing core content or user-facing information.SummaryDifference0.4%
- Check32 days agoChange DetectedMajor update: announces a version upgrade to v3.2.0 and publicly states funding-related operational notices, including that transactions may not be processed until appropriations are enacted.SummaryDifference1%
- Check39 days agoChange DetectedUpdate: replaced 'Plasma cell myeloma' with 'Multiple myeloma' and added MedlinePlus Genetics topic with revision to v3.1.0. Deletion removes the older term and v3.0.2.SummaryDifference0.2%
- Check47 days agoChange DetectedRemoved a MedlinePlus Genetics topic: Multiple myeloma, reducing the page’s coverage of that genetic topic. No new topics were added.SummaryDifference0.1%
Stay in the know with updates to Pembro + Lenalid Post-ASCT in High-Risk MM Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembro + Lenalid Post-ASCT in High-Risk MM Clinical Trial page.